In the third-quarter consolidated results for the fiscal year ending December 2026, the company reported recognition of non-operating expenses (including interest paid) and extraordinary losses. Foreign exchange losses decreased. Impairment loss amounted to 7,406 thousand yen. These items are reflected in the third-quarter financial summary for the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Carna Biosciences, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4572-20261106-03.pdf","jir_short_summary":"In the third-quarter consolidated results for the fiscal year ending December 2026, the company reported recognition of non-operating expenses (including interest paid) and extraordinary losses. Foreign exchange losses decreased. Impairment loss amounted to 7,406 thousand yen. These items are reflected in the third-quarter financial summary for the fiscal year ending December 2026.","jir_summary":"### Key Points of the Financial Results\nDuring the third-quarter consolidated period, non-operating expenses included interest paid, primarily due to amortization and interest on convertible bonds with stock acquisition rights. Issuance costs for bonds with stock acquisition rights were also recorded. Foreign exchange losses decreased due to exchange rate fluctuations, and foreign exchange gains were recorded in some periods. Foreign exchange losses for the third-quarter cumulative period totaled 4,845 thousand yen. Assets showing signs of impairment were written down to their recoverable amounts, and an impairment loss of 7,406 thousand yen was recorded. These items are reflected in the third-quarter financial summary for the fiscal year ending December 2026.\n\n### Future Impact and Notes\nThe above expense and loss recordings may affect indicators such as ordinary income for the current term; however, the main text does not specify concrete levels of revenue or operating income. Detailed financial indicators will be published in the financial summary, and investors should await the disclosure of that financial summary.","jir_financial_highlights":"Interest paid: 19,108 thousand yen (Unknown)\nIssuance costs of bonds with stock acquisition rights: 4,451 thousand yen (Unknown)\nForeign exchange gains from decreased foreign exchange losses: 4,267 thousand yen (Occurred)\nForeign exchange losses recorded (3Q cumulative): 4,845 thousand yen (Unknown)\nImpairment loss: 7,406 thousand yen (Unknown)","jir_category":"","jir_hashtags":"#CarnaBiosciences, #FinancialReport","jir_key_figures":"Interest paid: 19,108 thousand yen\nIssuance costs of bonds with stock acquisition rights: 4,451 thousand yen\nForeign exchange gains: 4,267 thousand yen\nCumulative foreign exchange losses: 4,845 thousand yen\nImpairment loss: 7,406 thousand yen","jir_meta_title":"Carna Biosciences, Inc. \u2014 Notice of Non-Operating Expenses and Extraordinary Losses\uff5cNovember 2026","jir_meta_description":"Carna Biosciences, Inc. announced the recording of non-operating expenses and extraordinary losses in its third-quarter results for the fiscal year ending December 2026. Summary includes interest paid, issuance costs for bonds with stock acquisition rights, foreign exchange loss status, and details of the impairment loss.","jir_og_title":"Carna Biosciences, Inc.\uff5cAnnouncement of Non-Operating Expenses and Extraordinary Losses","jir_og_description":"Summary of the recording of non-operating expenses and extraordinary losses in the third-quarter results. Review the upcoming financial summary for detailed financial indicators.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-143731","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n